Advertisement

Genzyme Corp. has completed the divestiture of its pharmaceutical intermediates business to International Chemical Investors Group (ICIG) – a plan the Cambridge company announced early in February.

Genzyme’s 120 employees in the business unit, operating mainly out of Liestal, Switzerland, have been employed by ICIG, as its pharmaceutical business in the company’s Corden Pharma company group. The employees will remain in Switzerland, with the U.S. sales and marketing office remaining in Boston.

SOURCE

Advertisement
Advertisement